Insys Therapeutics Inc   Report issue

For profit Phase 1 Phase 2 Phase 3
Founded: Chandler AZ United States (1990)
Status: No NME R&D (1990)

Organization Overview

First Clinical Trial
2000
NCT00024570
First Marketed Drug
2011
dronabinol (marinol)
First NDA Approval
None
Last Known Activity
2018

Timeline

NOW
  • Now

Mergers & Acquisitions

Historical Acquisition Tree

Alternative names

Chief Medical Officer, Insys Therapeutics Inc | INSYS DEV CO INC | INSYS THERAP | INSYS Therapeutics Inc

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Acute Pain (Phase 2)

Adrenocortical Carcinoma (Phase 1)

Amphetamine-Related Disorders (Phase 2)

Astrocytoma (Phase 2)

Breakthrough Pain (Phase 2)

Breast Neoplasms (Phase 2)

Cancer Pain (Phase 3)

Carcinoma (Phase 1)

Chronic Pain (Phase 3)

Dyspnea (Phase 3)

Emergencies (Phase 2)

Epilepsies, Myoclonic (Phase 3)

Epilepsy (Phase 3)

Epilepsy, Absence (Phase 2)

Glioblastoma (Phase 3)

Glioma (Phase 2)

Lennox Gastaut Syndrome (Phase 3)

Mucositis (Phase 3)

Neoplasms (Phase 1)

Oligodendroglioma (Phase 1)

Opioid-Related Disorders (Phase 1)

Pain, Postoperative (Phase 3)

Pancreatic Neoplasms (Phase 2)

Prader-Willi Syndrome (Phase 2)

Prostatic Neoplasms (Phase 2)

Seizures (Phase 3)

Spasm (Phase 3)

Spasms, Infantile (Phase 3)

Stomatitis (Phase 3)

Substance-Related Disorders (Phase 1)

Syndrome (Phase 3)

Overview

  • Highest Phase: Phase 3
  • # of Trials: 59
  • # of Trial APIs: 31